AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie definite-Lived Intangible Assets, Accumulated Amortization ($M) ($M)
Form 10-Q / 10-K Goodwill & Intangible Assets Note
Latest, Q2 2026
45,589
Period ended Jun 30, 2026
Change on a year earlier
+17.6%
38,757 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Definite-Lived Intangible Assets, Accumulated Amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 45,589 | +17.6% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 43,923 | +19.4% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 42,232 | +21.1% | Form 10-Q (filed 2026-08-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 40,445 | +22.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 38,757 | +24.4% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 36,792 | +23.1% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 34,877 | +24.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 33,086 | +25.0% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 31,149 | -7.3% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 29,890 | -5.2% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 28,026 | -5.5% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 26,469 | -4.6% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 33,607 | +30.4% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 31,537 | +31.5% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 29,645 | +33.8% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2022 | Sep 30, 2022 | 27,744 | +36.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 25,777 | +39.6% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 23,988 | +45.2% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 22,151 | +52.4% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2021 | Sep 30, 2021 | 20,360 | +60.6% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 18,467 | +75.1% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 16,524 | +80.9% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 14,536 | +67.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 12,676 | +51.6% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 10,547 | +32.2% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 9,133 | +17.0% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 8,696 | +17.1% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 8,362 | +17.7% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 7,980 | +17.6% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 7,804 | +16.1% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 7,424 | +16.2% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 7,107 | +15.6% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 6,785 | +15.5% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 6,723 | +19.2% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,391 | +19.1% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 6,148 | +19.1% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 5,874 | +18.5% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 5,641 | +9.9% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 5,366 | +8.0% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 5,164 | +7.0% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 4,956 | +5.4% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 5,135 | +10.9% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 4,967 | – | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2015 | Sep 30, 2015 | 4,827 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 4,702 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 4,631 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). AbbVie Definite-Lived Intangible Assets, Accumulated Amortization ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/intang_finite_accum
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.